Published in final edited form as:

J Acquir Immune Defic Syndr. 2015 June 1; 69(Suppl 2): S182–S190. doi:10.1097/QAI.0000000000000628.

Women who use or inject drugs: an action agenda for women-specific, multilevel and combination HIV prevention and research

Nabila El-Bassel, PhD¹ and Steffanie A. Strathdee, PhD²

¹Columbia University School of Social Work

²University of California San Diego School of Medicine

Abstract

Women account for more than half of all individuals living with HIV globally. Despite increasing drug and HIV epidemics among women, females who use drugs are rarely found in research, harm reduction programs, or drug and HIV treatment and care. Women who use drugs continue to face challenges that increase their vulnerability to HIV and other co-morbidities due to high rates of gender-based violence, human rights violations, incarceration, and institutional and societal stigmatization.

This special issue emphasizes how the burdens of HIV, drug use and their co-occurring epidemics affect women in a global context. Papers included focus on the epidemiology of HIV, HCV and other co-morbidities; HIV treatment, prevention, and care; and policies affecting the lives of female who use drugs. This issue also highlights the state of the science of biomedical and behavioral research related to women who use drugs.

The final paper highlights the major findings of papers covered and presents a call to action regarding needed research, treatment, and preventive services for women who use drugs. To address these needs, we advocate for women-specific thinking and approaches that considers the social, micro, and macro contexts of women's lives. We present a woman-specific risk environment framework that reflects the unique lives and contexts of women who use drugs and provide a call to action for intervention, prevention, and policies.

Keywords

Women; drugs; HIV

Global Burden of Drug Use and HIV among Women

Injection and non-injection drug use affect the health and well-being of millions of women worldwide. While women comprise one-third of all people who use drugs,¹ they do so in substantial numbers; global estimates from 2010 suggest that 4.7 million women are dependent on illicit opioid drugs, 6.3 million on amphetamines, and 2.1 million on

cocaine.²⁻⁴ An estimated 3.8 million women inject drugs.² The U.S. has recently seen a demographic shift in heroin consumption, with more women and white, middle-class, non-urban residents using the drug, as well as many women transitioning from prescribed opiates to heroin.⁵

The papers included in this special issue demonstrate a range of harmful physical, psychological, and social consequences of female drug use. Larney et al. found that substance-using women experience greater excess mortality than men who use drugs.⁷ Mortality from overdose of prescribed painkillers increased fivefold from 1999 to 2010, and excess mortality rates were also higher for women than for men.⁶ About 5,600 women in the U.S. died from prescription opiate overdose in 2010; four times as many as from heroin and cocaine overdose combined.⁶ Larney et al. also reviewed studies which identified higher HIV prevalence among women who inject drugs when compared to men who inject drugs.⁷

Other papers in this issue detail why drug use can create greater health burdens for women than for men. Page et al. and Springer et al. describe meager coverage of biomedical risk reduction treatments including Anti-Retroviral Therapy (ART), Opioid Substitution Therapy (OST), Opiate Agonist Therapy (OAT) and Pre-Exposure Prophylaxis (PrEP) for women.⁸ Gilbert et al. demonstrate that both injection and non-injection drug use among women are closely associated with a number of co-occurring disorders, including gender-based violence (GBV), trauma, and sexually transmitted infections (STIs), most notably HIV.⁹ Additionally, Iversen et al. demonstrate the extensive burden of HCV experienced by drug-using women: 60% of female injection drug users have been exposed to HCV, and 70 to 90% of HIV-positive women who inject drugs have co-morbid HCV infection.¹⁰ HIV-infected female drug users have significant HIV- and non-HIV-related medical needs, yet, as shown by Metsch et al., HIV testing and access to care remains low.¹¹ Furthermore, Blankenship et al. describe a range of structural barriers that complicate or prevent access to services for drug-using women.¹²

For certain sub-populations of women, drug use and HIV occur together with additional burdens. The paper by Strathdee et al. highlights intricate connections among drug use, sex work, and the criminal justice system.¹³ The size of the global sex industry is increasing, and approximately 30% of female sex workers (FSWs) inject or use drugs.¹³ Drug use is also a route to the criminal justice system; the vast majority (60%) of incarcerated women worldwide are serving time for drug-related offenses.¹ In the U.S., the number of women incarcerated for drug-related offenses has increased by more than 800% over the past 30 years, compared to a 300% increase for men.¹⁴ Furthermore, women in the criminal justice system often suffer from co-occurring physical and sexual abuse, trauma, and psychiatric disorders.¹⁵ There are disproportionate effects of incarceration on women's adherence to HIV care and treatment that persist post-release; women are significantly less likely than men to experience (1) retention in care, (2) ART prescription or optimal ART adherence, and (3) viral suppression.¹⁴

Impact of Limited Data

While the papers included highlight the extent of the challenges experienced by drug-using women, they also highlight substantial knowledge gaps (see Table 1). Women who use and inject drugs remain underrepresented in many drug trials, studies, and hence in systematic reviews. In this issue, Page et al. call for greater involvement of drug-using women in drug trials, Metsch et al. call for increased research on their access to HIV care, and Auerbach et al. call for greater consideration of gender theories in understanding risk environments.^{8,11,16}

Multiple papers in this issue describe difficulties in finding sex-disaggregated data on drug use, especially in low- and middle-income countries. Population-based studies of drug users rarely include women, making it difficult to estimate prevalence of female drug use. Special efforts are needed to recruit women for studies on substance use, and comprehensive surveillance systems to monitor and report drug trends by sex must also be developed. As Larney et al. describe, data on HIV prevalence among drug-using women is equally sparse. Of the 81 countries reporting data on HIV prevalence among people who inject drugs (PWID) to UNAIDS since 2011, only 48 reported data disaggregated by sex.⁷ Among reporting countries, there was considerable variation in HIV prevalence among women (0% to 65%).⁷ This may be a function of the small sample sizes of women and reliance on data from a limited number of locations.

Additionally, certain sub-populations of female drug users remain under-researched. Little attention has been given to HIV prevalence among women who use non-injection drugs, although non-injection drug use is also closely associated with HIV.¹⁷ Preliminary evidence suggests that women who have sex with women (WSW) have higher rates of drug use and higher prevalence of HIV relative to women with male sex partners only.^{18,19} Similarly, young transgender women show high rates of both non-injection²⁰ and injection drug use,^{21,22} with high self-reported HIV prevalence among those who use drugs.²³ Research on HIV among women and female adolescents who use drugs in the criminal justice system remains limited in low-and middle-income countries.

Finally, as Auerbach et al. describe, research on drug-using women lacks intersectionality, or a consideration of the ways in which race, class, and additional affiliations impact women's risk.¹⁶ Moreover, co-occurring disorders (e.g., substance use, violence and AIDS, or the "SAVA syndrome") among women is under-researched.⁹

The paucity of data regarding female substance users continues to undermine the effectiveness of risk reduction programs, compromises civil society's attempts to allocate funding for drug-using women, and relegates women-specific barriers to care as secondary concerns.

Gender-specific Risk Environments for HIV Faced by Women who Use Drugs

Over the past decade, there has been a surge in epidemiological, social science, modeling, and ecological research on the structural factors that shape HIV among PWID. Established frameworks consider the impact of various environments on risk behaviors among drug users.²⁴ However, conceptual approaches and prevention strategies tailored to women are lacking. As both Blankenship et al. and Auerbach et al. describe in their papers,^{12,16} approaches and programs for females are still driven by individual behavior-change theories and a male-focused perspective on the risk environment. In this paper, we use the same framework that was employed by Strathdee et al.^{13,24} to consider the gender-specific risk environment, focusing on both macro- and micro-level physical, social, economic, policy and legal influences and barriers to harm reduction and treatment services (see Table 2). Although many of the barriers described affect men as well, in most circumstances, they occur more frequently and severely for women.

Physical Risk Environment

Women who use drugs often live and work in physical settings that place them at high risk for acquiring HIV and other STIs. Blankenship et al. describe the challenges women who use drugs can face in physically accessing care. In many parts of the world, women may be geographically removed from harm reduction and drug treatment services. This is especially true of those who engage in sex work, which often occurs in remote locations far from services.²⁵ Harm reduction services may be available only during certain hours which conflict with employment or family responsibilities. Women who are homeless or lack proper documents may face additional problems in accessing harm reduction or HIV treatment. Lacking stable housing has been found to be associated with HIV risk behaviors.²⁶

As Springer et al. and Wechsberg et al. show in this special issue, even when women have the time and transportation to access harm reduction and drug treatment programs, these programs can be unfriendly or even hostile to women.^{27,28} In many countries, such programs are operated and attended primarily by men; they do not address needs specific to women, such as reproductive health, intimate partner violence (IPV), childcare responsibilities, or food insecurity.²⁸ As Gilbert et al. discuss, not many programs have been designed to simultaneously address SAVA syndemic components.⁹ Few women-only service centers exist, which can discourage access for some. Shelters offering other services may refuse to admit drug-using women, and admitting drug use can lead to increased instability (e.g., being evicted from housing).¹¹

Incarcerated women are generally far removed from harm reduction services. As of 2014, only 41 countries provided methadone or buprenorphine maintenance in prison and only nine operated prison-based needle and syringe programs (NSP).²⁹ Both ART and OAT are more likely to be available in men's prisons than in women's prisons.³⁰ Incarceration increases a woman's HIV risk and drug use in many ways. Incarcerated women lack access to care and social support. Isolation among female inmates is a source of anxiety and

depression, which can lead to increased substance use. Strathdee et al. confirm that some women initiate drug use in prison, switch from one substance to another, or begin a more harmful pattern of drug use with injection drugs to avoid detection by prison staff.^{13,31} In prisons without harm reduction services, sterile injection equipment is not available, and the likelihood of syringe-sharing increases.²⁹

Social Risk Environment

Several papers in this issue identify social inequalities that increase HIV vulnerabilities for women.^{12,16,28} Studies show that women tend to use or inject in social settings, and their social networks overlap with their drug use networks more than men's do.^{9,32} Women are more likely to experience their first drug injection with an intimate partner and to have that partner inject them.^{33,34} Refusal to share needles often symbolizes distrust and a denial of intimacy in a relationship, which can lead to IPV.³⁵ If women believe that such refusal might threaten the relationship and their safety, they may engage in unsafe injection practices.³⁶ Additionally, assisted injection among women has been found to be associated with increased risk of HIV infection. Women express a need to be injected by another because they have "weaker veins" or they lack the skills to locate and inject into a viable vein without scarring.³⁷ In contrast, most men quickly learn to self-inject and rarely permit their female sexual partners to inject them.³⁸ Therefore, women are often "second on the needle," as control over injection equipment is in the hands of their partner.³²

Women who use drugs are stigmatized more than men because of cultural stereotypes that hold women to different expectations and roles.³⁹ Women who use drugs are often portrayed as "bad" and "unfit" as mothers. Both stigma and criminalization of drug use during pregnancy drives women to hide their addiction from healthcare providers, keeping them from accessing harm reduction and HIV prevention.^{36,40} Stigma contributes to poor mental and physical health and interferes with drug treatment and recovery. Finally, women who use drugs may lack social supports such as childcare, due to stigma held by their families and friends.^{36,41}

As reviewed by Auerbach et al. in this special issue, the low social status of women and female adolescents who use or inject drugs leads to IPV and GBV as an extension of the unequal distribution of sexual, social, and economic power between men and women in drug-using subcultures.¹⁶ The prevalence of sexual and physical abuse is 3–5 times higher among drug-using women than among their non-using female counterparts.^{9,36} Physical IPV may create a context of fear and submission that makes it difficult for women to negotiate safer sex and for HIV-positive women to disclose their serostatus. Both Gilbert et al. and Wechsberg et al. discuss how HIV positive women who experience GBV and IPV are less likely to access HIV care, adhere to ART, and participate in HIV prevention and drug treatment services.^{9,28}

Economic Risk Environment

Globally, drug-using women experience high unemployment rates.⁴² Due to the stigma and discrimination described above, these women have minimal opportunities to access employment and become financially independent; many remain poor and depend on their

sexual partners for food and shelter.^{36,39,40,43} Such financial constraints reduce women's access to educational or vocational training, banking and asset accumulation, as well as property ownership. The papers by Blankenship et al. and Auerbach et al. show that financial gender inequality promotes IPV in relationships, reduces women's power in sexual negotiations with male partners, and increases their vulnerability to HIV.^{12,16}

Strathdee et al. discuss how depressed socioeconomic conditions can lead women to enter sex work,¹³ increasing their HIV risk.⁴⁴ Sex workers who are in debt have reduced negotiating power with clients, resulting in increases in unprotected sex and GBV.^{13,44} Indeed, a significant proportion (20–26%) of FSWs report engaging in unprotected sex in exchange for higher payments from their clients.^{44,45} Economic concerns are closely related to women's imprisonment; limited funding for HIV prevention and harm reduction in prisons, and the lack of funding for appropriate training of correctional staff are important economic barriers that increase prisoners' vulnerability to HIV and to HIV-related morbidity and mortality.⁴⁶

Policy/legal Risk Environment

Strathdee et al.'s paper describes the harsh legal and policy environment faced by drug-using women.¹¹ In some parts of the world, such as in Eastern Europe and Central Asia, drug treatment, arrest or even admission of drug use leads to registration as a drug user, which can have a range of detrimental and more severe consequences for women than men, including ineligibility for free ART and public housing, loss of one's driver's license, and police harassment.⁴⁷ Registration can be especially threatening to women whose parental rights can be jeopardized when their drug use is exposed. Discrimination against drug-using women by employers, doctors, courts, and educational institutions is often legal or overlooked.⁴⁸ Harsher punishments for women who use drugs and alcohol also exist in many countries, including corporal punishment.

Women's drug use can be exploited by police officers as justification for abuse and harassment. Aggressive policing includes arresting women for buying or carrying sterile syringes, harassment at needle exchange programs or drug treatment clinics, soliciting bribes to avoid arrest, sexual abuse and violence, or planting drugs on women.⁴⁹ As Strathdee et al. discuss, police worldwide have the authority to search, arrest, and detain both men and women for possession of small amounts of drugs, unused syringes, and drug paraphernalia.¹³ Studies of women worldwide have found a strong connection between substance use and police sexual misconduct, coercion, or rape,^{50,51} but little attention has been given to this serious human rights violation in the domains of research, prevention, and policy. Women may fail to report police abuses due to fears of imprisonment or other retributive consequences for themselves and their families.⁵⁰ Police abuses create micro risk environments in which drug-using women engage in riskier behaviors. Fears of police harassment, abuse, and confiscation of drug paraphernalia among women who smoke crack cocaine and inject drugs has been associated with increased HIV risk behaviors.²⁵

As Strathdee et al. report, sex work is illegal and criminalized in 116 countries,¹³ including countries that criminalize adult consensual sex and related transactions (buying, soliciting, or procuring), brothel-keeping, and management of sex work. A number of other laws are

used to target FSWs, including vagrancy, loitering, and public nuisance laws. Such laws increase vulnerability to violence and other risks by driving sex work underground.⁵²

Intervention Priorities

This dynamic interplay of HIV and drug use requires a multi-level approach to HIV prevention and treatment. Structural approaches, tailored to the specific needs of the population at risk, are crucial to HIV prevention and treatment.⁵³ Drawing on the papers included in this special issue, we now outline structural prevention approaches that consider the gender-specific risk environments (see Table 2).

Gender-specific Drug Treatment and Harm Reduction

A number of papers in this issue advocate for female outreach workers, female-specific services (e.g., reproductive health, child care), and access to comprehensive approaches that address trauma and mechanisms connecting SAVA syndemic components, as well as multi-level evidence-based HIV prevention approaches (e.g., couple and peer-led behavioral HIV interventions and social network interventions that train a member of the network to be a peer educator).^{12,16,28} Strathdee et al. call for female prison guards to supervise female inmates, in an effort to decrease sexual abuse. Governments must provide funding and ensure access to comprehensive HIV prevention strategies recommended by UNODC, WHO, and UNAIDS for people in harm reduction programs and in prisons. As HIV-infected women transitioning from jail experience greater co-morbidity and worse HIV treatment outcomes than men,¹⁴ future interventions that transition incarcerated people to community-based HIV clinical care should be gender-specific.

Protection of Legal Rights

Blankenship et al. call upon funders and civil society organizations to support advocacy efforts to repeal laws and policies that criminalize syringe possession, needle exchanges, and sex work. A recent modeling scenario in three cities (Vancouver, Canada; Bellary, India; and Mombasa, Kenya) found that full decriminalization of sex work could reduce HIV incidence among FSWs and clients by up to 43%.⁵² Additionally, Blankenship et al. advocate for the creation of safe places for women to inject drugs. These settings may reduce women's dependence on partners to inject them and in turn, may reduce syringe sharing.¹²

Reduction of Police Harassment

As Strathdee et al. discuss, there is a need to design, implement, and enforce policies to reduce police harassment and abuses in prisons and communities. Legislative reforms are needed along with police education programs such as those supported by the Law Enforcement and HIV Network.⁵⁴

Stigma Reduction Interventions

Blankenship et al. call for policies aimed at reducing inequality and exclusion that lie at the heart of drug use, HIV, and sex work-related stigmatization and discrimination.¹² The majority of existing stigma reduction interventions for substance-using women is based on social and cognitive-behavioral models; there is less emphasis on social conditions and

power that influences a woman's right to access services and resources. Therefore, there is a need to develop institutional or structural-level stigma interventions such as community-led mobilization which involves drug-using women and female adolescents in the change process, in order to force the creation and enforcement of laws against police harassment and abuses, and human rights violations.

Reducing Gender-based Violence

Blankenship et al. discuss the necessity of addressing GBV through community mobilization and advocacy efforts. Community mobilization interventions employ a range of strategies: social media, advocacy campaigns, and community activism aimed at changing gender-based norms associated with GBV and HIV risk behaviors. Campaigns should aim to change norms and attitudes towards drug-using women and female adolescents in order to enact laws that protect their rights and to encourage these women to seek life-saving health and other services. Targeted legislative, policy, and advocacy efforts are also needed to ensure that police, prosecutors, and judges are able to respond effectively to GBV cases.

Economic Interventions

Blankenship et al. describe microfinance interventions that help women increase access to legitimate employment, asset building, and business skills development.¹² Income-generating interventions have been documented to lead to reductions in sexual and drug risk behaviors especially among poor women and those engaged in sex work.^{55–57} Microfinance has been adapted less frequently for those who use or inject drugs. This might be due to a common value judgment that people who use drugs are not capable of becoming employable and committed to work.⁴²

Biomedical Treatment

As discussed by Page et al., the significant global reductions in HIV incidence and mortality that have occurred over the past decade⁵⁸ are largely due to increased access to ART among those living with HIV, which in turn are related to greater levels of viral suppression, and reduced likelihood of transmission to the uninfected, an effect referred to as HIV “treatment as prevention (TasP)”.^{8,59} In this special issue, Springer et al. describe the effectiveness of Medication Assisted Therapies (MAT) for opioid use (e.g., methadone; buprenorphine or buprenorphine/naloxone; oral naltrexone; extended-release naltrexone) in reducing frequency of injection and relapse to opioid use while improving health and social functioning and preventing transmission of HIV.²⁷ Yet the authors in this special issue emphasize that there has been little or no development of OAT specifically tailored for women, and that access to OAT for drug-using women is most constrained in the highest-need countries.²⁷ In many countries, multiple systems are in place to implement OAT and other harm reduction programs funded by NGOs and private practitioners when governments have been unsupportive.²⁷ For women who inject drugs, the overall state of access to harm reduction services is abysmal. A rallying cry from civil society and advocacy groups is sorely needed to move governments toward earnestly addressing the needs of women who inject drugs.

Finally, the contained environment of correctional settings could serve as a place where HIV, viral hepatitis, STIs, and drug and alcohol dependence can be diagnosed and treated. Strathdee et al. describe the limited availability of such programs in prisons and advocate for their expansion in all criminal justice settings.¹³

Combination HIV prevention

HIV research is yet to be able to elucidate what the best combinations of HIV prevention technologies are for women who use drugs. A number of papers in this special issue highlight the benefits of combination HIV prevention,^{8,11,27} which includes HIV counseling and testing; linkage to HIV care; access to NSP, OAT, MAT; and biomedical HIV prevention (e.g., diagnosis and treatment of sexually transmitted infections, daily PrEP, and vaginal gels such as 1% tenofovir or Topical PrEP). Extensive evidence indicates that high coverage of combination HIV prevention with behavioral and structural interventions can decrease HIV risk and vulnerability among women who use drugs.^{60,61} Biomedical prevention strategies such as ART and PrEP will be most successful if they are integrated into the multilevel and behavioral combination prevention strategies described in Table 2.

Page et al. stress that OAT and PrEP are not often offered to women who use drugs and efforts must be increased to boost access to these combination prevention strategies. The papers in this issue highlight the importance of integrating biomedical prevention to maximize benefits, and the need for scale-up of existing evidence-based interventions. However, in order to help women access combination prevention strategies, it is pivotal to eliminate the structural barriers identified in this special issue.

Although PrEP has been found to be efficacious in reducing HIV transmission, women who use drugs are absent in virtually all phases of PrEP research. Many scientific questions have not been answered about PrEP for these women or other key affected female populations such as sex workers, transgenders and those in the criminal justice system. Questions need to be answered such as: How acceptable is PrEP to women who use drugs? If drug using women want to use PrEP, what barriers exist? What gender-specific adherence *prevention* strategies are needed for women that are different than for men? Are there unique gender and *structural barriers* that exist for the use of PrEP? What gender-specific *adherence* strategies are needed for women who use drugs? Where and how should PrEP be packaged and distributed for these women?

Given the disappointing news from a number of PrEP HIV studies for women, the HIV field needs to consider other HIV technologies for prevention that will meet women's needs as well as new paradigms for improving adherence strategies. Without addressing these critical issues, we will not be able to advance women-specific HIV prevention and we will continue to blame women for the lack of success.

Conclusion

If problems such as gender inequalities, GBV, stigma, oppression, and co-morbidities are not addressed, they will continue to escalate and affect future generations of women. Drug use continues to increase globally among female adolescents and adults, as documented in a

number of the papers in this special issue. To combat global HIV/AIDS and substance use epidemics among women, this special issue underscores a critical need for attention to this population in all spheres and to improve policies that prevent them from accessing drug treatment, HIV care, and behavioral and biomedical prevention technologies and services. HIV and drug treatment services and harm reduction programs must be made more female-specific and accessible via creating policies to improve access to care and prevent incarceration. Policing practices must be changed and human rights violations eliminated. Governments and international NGOs must generate the political will necessary to increase funding for programs that address the unique contexts of women's lives and the root social causes of drug use and HIV that women face. Governments need to understand that the lack of attention to education, employment opportunities and rights for women and female adolescents are rooted in the oppression of women and that some consequences of such oppression lead to drug use, sex work, and transmission of HIV. Interrupting intergenerational drug use, HIV, HCV and co-morbidities like mental illness should be a priority. Decriminalization of drug use and sex work is an important structural intervention in the legal and policy environment that can reduce the risk of HIV transmission among vulnerable women. We also call for attention to those women who have been overlooked, namely women who have sex with women, transgender individuals and women involved in the criminal justice system.

HIV prevention and treatment approaches for substance-using women must move beyond an individual focus to a multi-level one, and be tailored to the realities faced by these women. Researchers and funders must see gender as more than a control variable or a sampling issue in their studies. HIV and drug use research must include a sufficient number of female participants so that the scientific conclusions lack gender biases. More gender-inclusive results will better equip researchers, policy makers, providers to meet women's needs and challenges. Moreover, additional research and funding should be invested in microbicide and PrEP research for women who use drugs with a concomitant investment to respond to their needs and structural vulnerabilities that increase their risk for HIV and prevent them from accessing prevention and treatment.

Acknowledgments

Dr. El-Bassel acknowledges partial support received from R01s (DA-033168) funded by the National Institute of Drug Abuse from the National Institute of Health and through HIV Prevention Trials Network (UM1 068619).

Dr. Strathdee acknowledges partial support received from the National Institute on Drug Abuse (R37 DA019829) and from the National Institute of Health through HIV

References

1. UNOCD. World Drug Report 2014. UNODC; 2014.
2. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. *Lancet*. Nov 9; 2013 382(9904):1564–1574. [PubMed: 23993281]
3. Degenhardt L, Charlson F, Mathers B, et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. *Addiction* (Abingdon, England). Aug; 2014 109(8):1320–1333.

4. Degenhardt L, Baxter AJ, Lee YY, et al. The global epidemiology and burden of psychostimulant dependence: findings from the Global Burden of Disease Study 2010. *Drug and alcohol dependence*. Apr 1; 2014 137:36–47. [PubMed: 24559607]
5. Cicero TJ, Kuehn BM. Driven by prescription drug abuse, heroin use increases among suburban and rural whites. *Jama*. Jul; 2014 312(2):118–119. [PubMed: 25005636]
6. CDC. Vital Signs: Overdoses of Prescription Opioid Pain Relievers and Other Drugs Among Women - United States, 1999–2010. CDC; 2013.
7. Larney S, Mathers BM, Poteat T, Kamarulzaman A, Degenhardt L. Global epidemiology of HIV among women and girls who use and inject drugs: current knowledge and limitations of the data. *Journal of acquired immune deficiency syndromes (1999)*. 2015
8. Page K, Tsui J, Maher L, Choopanya K, Vanichseni S, Mock PA, Celum C, Martin M. Biomedical HIV prevention including PreP and opiate agonist therapy for women who inject drugs: state of research and future directions. *Journal of acquired immune deficiency syndromes (1999)*. 2015
9. Gilbert L, Raj A, Hien D, Stockman J, Terlikbayeva A, Wyatt G. Targeting the SAVA (substance abuse, violence and AIDS) Syndemic among women and girls: a global review of epidemiology and integrated interventions. *Journal of acquired immune deficiency syndromes (1999)*. 2015
10. Iversen J, Page K, Madden A, Maher L. HIV, HCV and health-related harms among women who inject drugs: implications for prevention and treatment. *Journal of acquired immune deficiency syndromes (1999)*. 2015
11. Metsch L, Philbin MM, Parish C, Shiu K, Frimpong JA, Giang LM. HIV testing, care, and treatment among women who use drugs from a global perspective: progress and challenges. *Journal of acquired immune deficiency syndromes (1999)*. 2015
12. Blankenship KM, Reinhard E, Sherman SG, El-Bassel N. Structural Interventions for HIV Prevention Among Women Who Use or Inject Drugs: A Global Perspective. *Journal of acquired immune deficiency syndromes (1999)*. 2015
13. Strathdee SA, West BS, Reed E, Moazan B, Azim T, Dolan K. Substance use and HIV among female sex workers and female prisoners: risk environments and implications for prevention, treatment and policies. *Journal of acquired immune deficiency syndromes (1999)*. 2015
14. Meyer JP, Zelenev A, Wickersham JA, Williams CT, Teixeira PA, Altice FL. Gender Disparities in HIV Treatment Outcomes Following Release From Jail: Results From a Multicenter Study. *American journal of public health*. Jan 16; 2014 104(3):434–441. [PubMed: 24432878]
15. Iakobishvili, E. Cause for alarm: the incarceration of women for drug-related offences in Europe and Central Asia, and the need for legislative and sentencing reform. London, UK: International Harm Reduction Association; 2012.
16. Auerbach JD, Smith LR. Theoretical Foundations of Research Focused on HIV Prevention Among Women Who Use Drugs: Whither Gender? *Journal of acquired immune deficiency syndromes (1999)*. 2015
17. Shoptaw S, Montgomery B, Williams CT, et al. Not just the needle: the state of HIV-prevention science among substance users and future directions. *Journal of acquired immune deficiency syndromes (1999)*. Jul; 2013 63(Suppl 2):S174–178. [PubMed: 23764632]
18. Ompad DC, Friedman SR, Hwang SJ, Nandi V, Fuller CM, Vlahov D. HIV risk behaviors among young drug using women who have sex with women (WSWs) in New York City. *Substance use & misuse*. 2011; 46(2–3):274–284. [PubMed: 21303247]
19. Friedman SR, Ompad DC, Maslow C, et al. HIV prevalence, risk behaviors, and high-risk sexual and injection networks among young women injectors who have sex with women. *American journal of public health*. Jun; 2003 93(6):902–906. [PubMed: 12773350]
20. Rowe CSG-M, McFarland W, Wilson EC. Prevalence and correlates of substance use among trans-female youth ages 16–24 years in the San Francisco Bay Area. *Drug and alcohol dependence*. In press.
21. Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. *The Lancet. Infectious diseases*. Mar; 2013 13(3):214–222. [PubMed: 23260128]

22. Hounsfield VL, Freedman E, McNulty A, Bourne C. Transgender people attending a Sydney sexual health service over a 16-year period. *Sexual health*. Sep; 2007 4(3):189–193. [PubMed: 17931532]
23. Bowers JR, Branson CM, Fletcher JB, Reback CJ. Predictors of HIV Sexual Risk Behavior among Men Who Have Sex with Men, Men Who Have Sex with Men and Women, and Transgender Women. *International journal of sexual health : official journal of the World Association for Sexual Health*. 2012; 24(4):290–302. [PubMed: 24660042]
24. Rhodes T. The ‘risk environment’: a framework for understanding and reducing drug-related harm. *International Journal of Drug Policy*. Jun; 2002 13(2):85–94.
25. Shannon K, Rusch M, Shoveller J, Alexson D, Gibson K, Tyndall MW. Mapping violence and policing as an environmental-structural barrier to health service and syringe availability among substance-using women in street-level sex work. *The International journal on drug policy*. Apr; 2008 19(2):140–147. [PubMed: 18207725]
26. Reed E, Gupta J, Biradavolu M, Devireddy V, Blankenship KM. The role of housing in determining HIV risk among female sex workers in Andhra Pradesh, India: considering women's life contexts. *Social science & medicine* (1982). Mar; 2011 72(5):710–716. [PubMed: 21306811]
27. Springer SA, Larney S, Mehrjerdi ZA, Altice FL, Metzger D, Shoptaw S. Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: progress, gaps and future directions. *Journal of acquired immune deficiency syndromes* (1999). 2015
28. Wechsberg WM, Deren S, Myers B, Kirtadze I, Zule WA, Howard B, El-Bassel N. Gender-specific HIV prevention interventions for women who use alcohol and other drugs: state of the science and future directions. *Journal of acquired immune deficiency syndromes* (1999). 2015
29. Dolan, K. HIV prevalence in prison: a global overview. Paper presented at: The 20th International AIDS Conference; 2014; Melbourne, Australia.
30. Pinkham S, Stoicescu C, Myers B. Developing Effective Health Interventions for Women Who Inject Drugs: Key Areas and Recommendations for Program Development and Policy. *Advances in Preventive Medicine*. 2012
31. Martin RE, Gold F, Murphy W, Remple V, Berkowitz J, Money D. Drug use and risk of bloodborne infections: a survey of female prisoners in British Columbia. *Canadian journal of public health = Revue canadienne de sante publique*. Mar-Apr;2005 96(2):97–101. [PubMed: 15850026]
32. El-Bassel N, Shaw SA, Dasgupta A, Strathdee SA. People who inject drugs in intimate relationships: it takes two to combat HIV. *Current HIV/AIDS reports*. Mar; 2014 11(1):45–51. [PubMed: 24477931]
33. Simmons J, Rajan S, McMahon JM. Retrospective accounts of injection initiation in intimate partnerships. *International Journal of Drug Policy*. Jul; 2012 23(4):303–311. [PubMed: 22398215]
34. Rhodes, T.; Wagner, K.; Strathdee, S.; Davidson, P.; Bourgois, P. Structural Violence and Structural Vulnerability Within the Risk Environment: Theoretical and Methodological Perspectives for a Social Epidemiology of HIV Risk Among Injection Drug Users and Sex Workers. In: O'Campo, P.; Dunn, J., editors. *Rethinking Social Epidemiology: Towards a Science of Change*. Springer; Netherlands: 2012. p. 205-230.
35. Seear K, Gray R, Fraser S, Treloar C, Bryant J, Brener L. Rethinking safety and fidelity: The role of love and intimacy in hepatitis C transmission and prevention. *Health Sociology Review*. 2012; 12(3):272–286.
36. El-Bassel N, Gilbert L, Witte S, Wu E, Chang M. Intimate partner violence and HIV among drug-involved women: contexts linking these two epidemics--challenges and implications for prevention and treatment. *Substance use & misuse*. 2011; 46(2–3):295–306. [PubMed: 21303249]
37. Tuchman E. Women and addiction: the importance of gender issues in substance abuse research. *Journal of addictive diseases*. Apr; 2010 29(2):127–138. [PubMed: 20407972]
38. Wagner KD, Jackson Bloom J, Hathazi SD, Sanders B, Lankenau SE. Control over Drug Acquisition, PrePreparation, and Injection: Implications for HIV and HCV Risk among Young Female Injection Drug Users. *ISRN Addiction*. 2013; 2013
39. El-Bassel N, Wechsberg WM, Shaw SA. Dual HIV risk and vulnerabilities among women who use or inject drugs: no single prevention strategy is the answer. *Current opinion in HIV and AIDS*. Jul; 2012 7(4):326–331. [PubMed: 22498480]

40. El-Bassel N, Gilbert L, Wu E, Go H, Hill J. Relationship between drug abuse and intimate partner violence: a longitudinal study among women receiving methadone. *American journal of public health*. Mar; 2005 95(3):465–470. [PubMed: 15727978]
41. El-Bassel N, Gilbert L, Goddard-Eckrich D, et al. Efficacy of a Group-Based Multimedia HIV Prevention Intervention for Drug-Involved Women under Community Supervision: Project WORTH. *PloS one*. 2014; 9(11):e111528. [PubMed: 25372149]
42. Sherman SG, German D, Cheng Y, Marks M, Bailey-Kloche M. The evaluation of the JEWEL project: an innovative economic enhancement and HIV prevention intervention study targeting drug using women involved in prostitution. *AIDS care*. Jan; 2006 18(1):1–11. [PubMed: 16282070]
43. Kirtadze I, Otiashvili D, O'Grady KE, et al. Twice stigmatized: provider's perspectives on drug-using women in the Republic of Georgia. *Journal of psychoactive drugs*. Jan-Mar;2013 45(1):1–9. [PubMed: 23662326]
44. Reed E, Gupta J, Biradavolu M, Devireddy V, Blankenship KM. The context of economic insecurity and its relation to violence and risk factors for HIV among female sex workers in Andhra Pradesh, India. *Public Health Reports*. Jul-Aug;2010 125(Suppl 4):81–89. [PubMed: 20629253]
45. Ntumbanzondo M, Dubrow R, Niccolai LM, Mwandagaliwa K, Merson MH. Unprotected intercourse for extra money among commercial sex workers in Kinshasa, Democratic Republic of Congo. *AIDS care*. Oct; 2006 18(7):777–785. [PubMed: 16971288]
46. Sumartojo E. Structural factors in HIV prevention: concepts, examples, and implications for research. *AIDS (London, England)*. Jun; 2000 14(Suppl 1):S3–10.
47. El-Bassel N, Shaw SA, Dasgupta A, Strathdee SA. Drug use as a driver of HIV risks: re-emerging and emerging issues. *Current opinion in HIV and AIDS*. Mar; 2014 9(2):150–155. [PubMed: 24406532]
48. Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. *Addiction (Abingdon, England)*. Feb; 2004 99(2):209–214.
49. Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. *Current HIV/AIDS reports*. May; 2010 7(2):99–106. [PubMed: 20425564]
50. Cottler LB, O'Leary CC, Nickel KB, Reingle JM, Isom D. Breaking the blue wall of silence: risk factors for experiencing police sexual misconduct among female offenders. *American journal of public health*. Feb; 2014 104(2):338–344. [PubMed: 24328629]
51. Odinkova V, Rusakova M, Urada LA, Silverman JG, Raj A. Police sexual coercion and its association with risky sex work and substance use behaviors among female sex workers in St. Petersburg and Orenburg, Russia. *The International journal on drug policy*. Jan; 2014 25(1):96–104. [PubMed: 23916802]
52. Shannon K, Goldenberg SM, Deering KN, Strathdee SA. HIV infection among female sex workers in concentrated and high prevalence epidemics: why a structural determinants framework is needed. *Current opinion in HIV and AIDS*. Mar; 2014 9(2):174–182. [PubMed: 24464089]
53. Gupta GR, Parkhurst JO, Ogden JA, Aggleton P, Mahal A. Structural approaches to HIV prevention. *Lancet*. Aug 30; 2008 372(9640):764–775. [PubMed: 18687460]
54. Network LEaH. [Accessed January 29th, 2015] Law Enforcement and HIV Network. <http://www.leahn.org/>
55. Dworkin SL, Blankenship K. Microfinance and HIV/AIDS prevention: assessing its promise and limitations. *AIDS and Behavior*. 2009; 13(3):462–469. [PubMed: 19294500]
56. Stratford D, Mizuno Y, Williams K, Courtenay-Quirk C, O'Leary A. Addressing poverty as risk for disease: recommendations from CDC's consultation on microenterprise as HIV prevention. *Public health reports*. 2008; 123(1):9. [PubMed: 18348475]
57. Cui RR, Lee R, Thirumurthy H, Muessig KE, Tucker JD. Microenterprise Development Interventions for Sexual Risk Reduction: A Systematic Review. *AIDS and Behavior*. 2013; 17(9): 2864–2877. [PubMed: 23963497]
58. UNAIDS. Global Report 2012. Geneva, Switzerland: UNAIDS; 2012.

59. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. *New England Journal of Medicine*. 2011; 365(6):493–505. [PubMed: 21767103]
60. Jürgens R, Csete J, Amon JJ, Baral S, Beyrer C. People who use drugs, HIV, and human rights. *The Lancet*. 2010; 376(9739):475–485.
61. Medicine Io. Preventing HIV infection among injecting drug users in high-risk countries. Washington, D.C: National Academies Press; 2007.

Table 1**Research Gaps on HIV in Women who Use Drugs**

Research Questions	Study needed
<i>Epidemiology</i>	
How prevalent is drug use among women in low and middle income countries?	Sex-disaggregated statistics in country-level studies as well as global surveillance systems on all different drugs including prescribed painkillers
How prevalent is drug use among certain sub-populations of women?	Population-based studies of WSW, transgender women, incarcerated women, sex workers, adolescents and girls
How prevalent is HIV in women who use drugs?	Epidemiological studies globally, but primarily in middle and low- income countries, with sex-disaggregated data
How prevalent are co-occurring disorders such as HIV, violence, etc. among women who use drugs?	Population-based and epidemiological studies of SAVA syndemic (Substance Use, Violence, and AIDS factors and other co- occurring disorders
How prevalent is HIV among drug- using women in the criminal justice system?	Epidemiological studies that take place among groups of incarcerated women and women in alternative to incarceration programs.
How prevalent is HIV among non- injection drug users?	Epidemiological studies of HIV prevalence among women and girls who use, but don't inject, drugs and alcohol.
<i>Basic Research</i>	
What forms of vaginal and rectal microbicides will be acceptable, safe and effective for women who use drugs?	Inclusion of women who use drugs in phase 1 and phase 2 trials of microbicides
What forms of oral or injectable PreP will be acceptable, safe and effective for women who use drugs?	Inclusion of women who use drugs in phase 1 and phase 2 trials of PreP
<i>HIV Prevention</i>	
What interventions will reduce HIV incidence for women who use drugs and have co-occurring disorders such as violence, etc.?	Population-based studies of SAVA syndemic factors and other co- occurring disorders
<i>Improvement of care</i>	
How well do harm reduction and drug treatment services reach women?	Sex-disaggregated surveillance data on harm reduction and drug treatment services
How to maximize effectiveness of interventions for women?	Interventions studies (all stages) for women, especially in biomedical research.
<i>Structural change</i>	
What is the effect of decriminalization of drug use and sex work?	Population-based longitudinal or comparative studies that examine effects of decriminalization on access to harm reduction. Some research, including theoretical modelling studies exist, but because these behaviors are criminalized in most countries worldwide, not many research opportunities exist.
How might police education programs reduce HIV risks among women who use drugs?	Longitudinal studies to examine the impact of police education programs on HIV risk behaviors of women who use drugs, including sex workers.
How do the institutions of race, ethnicity, and class interact with gender to heighten risk among drug-using women?	Consideration of intersectionality in formative research and mathematical models with PWID, disaggregated by sex. Studies should include a diverse sample of drug-using women.

Table II
Risk Environment for HIV among Women Who Use Drug Use and Potential Interventions

	Micro-level Factors	Macro-level Factors	Possible Interventions
Physical	<ul style="list-style-type: none"> Harm reduction, drug treatment and HIV treatment services may be inaccessible, particularly for women Women may feel unwelcome/unsafe at drug treatment and harm reduction programs Few legal/safe places for women to inject or use drugs Women may have few legal/safe places to sell sex Due to drug-using status, women may be denied access to shelters or access to special services (e.g. IPV shelters) Few prisons provide HIV and drug treatment services In prison environment, access to clean injection equipment is limited 	<ul style="list-style-type: none"> Women's lower mobility (especially in suburban and rural settings) Drug treatment and harm reduction programs are typically designed for men Hostile street environment created by policing Homelessness and dislocation Harsh prison environment including sexual abuse by other inmates and staff in prison 	<ul style="list-style-type: none"> Expansion/restructuring of existing drug treatment and harm reduction services to improve women's access to them, including strengthening outreach efforts, use peers as outreach workers, provide transportation to clinics, mobile clinics, and childcare at clinics Development of interventions and services designed for women that consider childcare, reproductive health, parenting skills, and women-only centers Integration of health and social services, offering "a one stop shop" model of services (multiple services in one location), strengthening referral networks among various services Establish "safe" injection spaces for women with support staff and sterile equipment Establish legal "safe" spaces where women can trade sex without police interference and harassment Outreach to homeless women, provide housing Establish drug treatment programs, HIV treatment programs and harm reduction programs in prisons
Social	<ul style="list-style-type: none"> Gender roles and relationships with sexual partners may prevent women from accessing harm reduction services or lead to forced unsafe sex Weak social support from family and friends (particularly when incarcerated) Experience of violence (IPV and GBV) Experience of stigma at clinics and service centers, particularly towards women Isolation of women in prison encourages drug use 	<ul style="list-style-type: none"> Social marginalization of women Gendered organization of drug-using networks Acceptance of GBV/IPV as a cultural norm Structural and individual stigma towards women who use drugs (and related stigmas towards sex workers, HIV+ women, etc.) 	<ul style="list-style-type: none"> Reduce stigma among service providers by improving provider attitudes towards women who use drugs, improving provider-patient relationships, and changing organizational culture Reduction of GBV and IPV in the wider community through mobilization interventions targeting norms and cultural practices Reduce police harassment of female drug users and sex workers through sensitivity training
Economic	<ul style="list-style-type: none"> Women lack financial resources or may be in debt 	<ul style="list-style-type: none"> Gender biases and stigma discourage women from being financially independent 	<ul style="list-style-type: none"> Increase drug-using women's access to legitimate employment through job training programs, end employment discriminatory

	Micro-level Factors	Macro-level Factors	Possible Interventions
	<ul style="list-style-type: none"> • Women may be economically dependent on their partner and others in their drug networks • Women are denied employment opportunities due to drug use or related histories of sex work or incarceration • Women are often denied government financial aid due to drug use histories 	<ul style="list-style-type: none"> • Few employment/training programs for women who use drugs • Little funding for women-specific HIV prevention, treatment and harm reduction programming in communities • Little funding for women-specific HIV prevention, treatment and harm-reduction in prisons 	<ul style="list-style-type: none"> • practices against women who use drugs, create job opportunities for women who use drugs • Asset-building, including microfinance programs
Policy/legal	<ul style="list-style-type: none"> • Drug-related arrests of women • Aggressive policing • Service providers don't adhere to confidentiality rules or such rules don't exist • Denial of welfare or loss of government housing/benefits due to women's drug use 	<ul style="list-style-type: none"> • Criminalization of drug use/possession (including drug use during pregnancy) • Criminalization of sex work • Policing policies that target drug users and sex workers • Policies that separate women drug users from their children during drug treatment • Limited funding for women-specific programming in communities and in prisons 	<ul style="list-style-type: none"> • Decriminalization of drug use/protection and sex work • Establish social protections for women who use drugs, including removal of laws that require registration of drug users, removal of laws that allow children to be taken from mothers who use drugs, removal of laws that criminalize drug use during pregnancy • Ensure the interests of drug-using women are represented in local and national discourse, encourage drug-using women to organize and advocate for their interests